Recruiting

Testing a new injectable medication for type 2 diabetes

Plain-English translation of NCT07064486 on ClinicalTrials.gov ↗ · Source last updated October 2025 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called to see how well it works for people with type 2 diabetes who are already taking metformin. You would receive one injection per week, and researchers want to compare how well this medication works compared to a medication called , which is already used to treat diabetes. The study will measure blood sugar control and monitor for any side effects.

People with type 2 diabetes often need more than one medication to control their blood sugar, and doctors are always looking for new treatment options that work well and are safe. This trial will help determine whether this medication could become another useful choice for patients.

Do you qualify?

You likely qualify if…

you have been diagnosed with type 2 diabetes
you have been taking metformin at a stable dose of at least 1,000 mg per day for at least 8 weeks before joining
your BMI is 23 kg/m² or higher at screening
your weight has been stable (within 5%) for at least 3 months before the study
your blood sugar control (HbA1c) is between 7.5% and 11.0% at screening

You likely don't qualify if…

you have been diagnosed with type 1 diabetes or another special type of diabetes
you have a history of cancer in the past 5 years (except non-melanoma skin cancer), or you are being evaluated for cancer
you have a history of pancreatitis (inflammation of the pancreas)
you are allergic to GLP-1 medications or metformin, or you have severe allergies to multiple foods or medications
you have had 2 or more severe low blood sugar episodes in the past year

What participation looks like

If you join this trial, you will be randomly assigned to receive one of three treatments: either 5 mg of , 10 mg of , or 1 mg of — each given as an injection under the skin once per week. You will continue taking your metformin as usual. The study takes place in Indonesia and will involve regular visits to check your blood sugar levels, monitor how well the medication is working, and watch for any side effects.

AI-generated summary from trial data · Jun 1, 2026 · Not medical advice

Trial locations(4 sites)

Indonesia

RS Universitas Indonesia, Depok, West Java

RSUP Fatmawati, Jakarta

RSUP Persahabatan, Jakarta

RSUPN Dr. Cipto Mangunkusumo, Jakarta